1. Home
  2. BGLC vs OGEN Comparison

BGLC vs OGEN Comparison

Compare BGLC & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BGLC
  • OGEN
  • Stock Information
  • Founded
  • BGLC 2017
  • OGEN 1996
  • Country
  • BGLC Malaysia
  • OGEN United States
  • Employees
  • BGLC N/A
  • OGEN N/A
  • Industry
  • BGLC Medical Specialities
  • OGEN Biotechnology: Pharmaceutical Preparations
  • Sector
  • BGLC Health Care
  • OGEN Health Care
  • Exchange
  • BGLC Nasdaq
  • OGEN Nasdaq
  • Market Cap
  • BGLC 7.6M
  • OGEN 4.5M
  • IPO Year
  • BGLC N/A
  • OGEN N/A
  • Fundamental
  • Price
  • BGLC $0.37
  • OGEN $0.34
  • Analyst Decision
  • BGLC
  • OGEN
  • Analyst Count
  • BGLC 0
  • OGEN 0
  • Target Price
  • BGLC N/A
  • OGEN N/A
  • AVG Volume (30 Days)
  • BGLC 117.9K
  • OGEN 392.1K
  • Earning Date
  • BGLC 11-20-2024
  • OGEN 11-07-2024
  • Dividend Yield
  • BGLC N/A
  • OGEN N/A
  • EPS Growth
  • BGLC N/A
  • OGEN N/A
  • EPS
  • BGLC N/A
  • OGEN N/A
  • Revenue
  • BGLC $9,183,168.00
  • OGEN $7,466.00
  • Revenue This Year
  • BGLC N/A
  • OGEN N/A
  • Revenue Next Year
  • BGLC N/A
  • OGEN N/A
  • P/E Ratio
  • BGLC N/A
  • OGEN N/A
  • Revenue Growth
  • BGLC N/A
  • OGEN N/A
  • 52 Week Low
  • BGLC $0.31
  • OGEN $0.29
  • 52 Week High
  • BGLC $3.39
  • OGEN $7.74
  • Technical
  • Relative Strength Index (RSI)
  • BGLC 32.80
  • OGEN 36.96
  • Support Level
  • BGLC $0.38
  • OGEN $0.29
  • Resistance Level
  • BGLC $0.49
  • OGEN $0.35
  • Average True Range (ATR)
  • BGLC 0.02
  • OGEN 0.04
  • MACD
  • BGLC -0.01
  • OGEN 0.02
  • Stochastic Oscillator
  • BGLC 5.94
  • OGEN 31.19

About BGLC BioNexus Gene Lab Corp Common stock

BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.

About OGEN Oragenics Inc.

Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.

Share on Social Networks: